CFA Society San Diego’s Post

In a recent GlobeSt story about the life sciences sector, I was able to give some insight on the expansion of life sciences investments and emerging markets. Life sciences investments are expanding beyond Boston and San Diego into secondary markets like Florida. Site selection factors include proximity to universities, existing operations, and infrastructure considerations. Companies are also exploring specialized development, such as cGMP production and vivarium spaces. The onshore production need, emphasized during the pandemic, remains crucial. Emerging markets are witnessing significant growth in the bioscience healthcare workforce, attracting startups and established companies. The industry is diversifying geographically to seize various opportunities and support future advancements. https://lnkd.in/eba-nFxY #LifeSciences #ResearchCollaboration #WorkforceDevelopment #DevelopmentTrends #BioResearch 

Discover the Future with Our Investing in Longevity Course! Tailored for venture capitalists, pharma executives, and biotech professionals, this course offers a deep dive into the latest in longevity tech. Learn about advancements, key players, and potential risks and rewards from leading experts. Completed the ILC course yet? If not, what are you waiting for? Enroll now at longevity.degree and start investing in the future today!

Boston remains the #1 Life Sciences cluster in the U.S. In 2024, Boston continues to be the top Life Sciences cluster nationally. Explore key insights about the Boston market in the latest JLL Life Sciences Real Estate Perspective and Cluster Analysis. - Boston remains the #1 Life Sciences cluster in the U.S., with unmatched talent and innovation depth - Demand is rebounding, with 2.8 million square feet of demand as of August 2024, a 34% increase year-over-year - Venture capital investment is on pace for its second-best year on record, with $3.0 billion invested year-to-date Despite short-term hurdles, Boston's Life Sciences sector shows resilience and signs of recovery. The focus on smaller spaces and strong venture funding bode well for future growth. To understand the factors that make Boston the top Life Sciences market in the U.S. read the full report: https://lnkd.in/e4e9KgVX

Read this interesting article written by my colleague Laurie Burlingame if you want to learn how to navigate life sciences M&A in 2024. https://lnkd.in/e-SfnuPk

Bio€quity Europe is off to an outstanding start with the convergence of life sciences companies, investors, local and EU government, and those of us who support our clients in further support of advancing global public health! Our session today was moderated by Selina Koch, PhD , BioCentury Inc. and included Jennifer McMahon, Seroba, Edward Kliphuis, Sofinnova Partners, John W Cassidy, Kindred Capital VC, Florent Gros, Earlybird Venture Capital. I was thrilled to join such an outstanding group of investors to discuss the opportunities for AI to influence drug discovery, research and development! #BioEquityEurope

2023 was quite the roller coaster....so this is very promising to hear; especially the stability! We've been hearing rumblings across the board from our clients to be ready - and we are more than ready!! We’re working with some great candidates right now that are open to all hiring solutions – whether it’s a short-term project, an established contract position, or a full-time perm opening – we’ve got you covered! I know we can deliver for your team…we just need an audience and an opportunity to shine! #Beready #lifesciences #biometrics #biostatistics #programming #datamanagement #clinicaloperations #clinicaldevelopment #medicalaffairs #regulatoryaffairs #drugsafety

Interested in receiving feedback on your pitch, but maybe it’s too early for funding?   Apply to MABA's 1st Pitch Life Science Office Hours today to refine your pitch and connect with life science angel investors. MABA Office Hours provide constructive feedback to companies that may be too early for funding and those who wish to pitch for feedback. - Office hours are open to all to attend but are intended for companies in MABA’s general areas of investment interest (therapeutics, devices, diagnostics, digital health) - Companies pitch for 10 minutes to a panel of MABA investors, followed by 10 minutes of feedback Companies interested in pitching should apply at this link: https://lnkd.in/eF8smZiw #MABA #angelinvestors #lifesciences #1stpitchlifesciences

Biotech Equity Research: Tracking The Promise (And Risk) Of Early Stage Companies Navigating The Public Markets October 3, 2024, 3:00 – 4:00 p.m. EST Speaker: Benjamin J. Burnett, PhD, Managing Director, Equity Research, Stifel Investment Services Ben Burnett, Biotech Equity Research Analyst at Stifel will discuss the intersection of early stage life science companies and finance. We plan to cover recent capital market trends and forecasts, timing the market, and what it takes to become (and be) a public company. Balancing innovation with capital needs requires a good understanding of how and when to access capital, and whether or not this is more easily done as a private or public company. We plan to delve into these concepts in detail and walk through informative case studies of both success and failure.  Zoom Registration: https://lnkd.in/e-hHmpN7

In the beginning of January, our international Life Sciences team, including Ross McNaughton, Adrian Toutoungi, Colin McCall, Dr. Stefanie Greifeneder, Niclas von Woedtke and Sarah Cole, attended the J.P. Morgan Healthcare Conference to connect with global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community. Cautious optimism was the prevailing attitude amongst biotech CEOs and investors. Read more on the key themes of discussion at this year's conference, which we expect to be major topics throughout 2024: https://bit.ly/3unOLcU   #LifeSciences #TechInvestors #PrivateWealth 

𝐃𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐢𝐬 𝐧𝐨𝐭 𝐚 𝐬𝐨𝐥𝐨 𝐦𝐢𝐬𝐬𝐢𝐨𝐧 🚀   In the high-stakes world of life sciences, innovation is booming, but so are the challenges. As the pace of R&D accelerates, navigating the complex path from concept to clinical success often requires more than just a great idea—it demands a strategic, expert-driven approach. At 2 Bridge, we believe that overcoming these hurdles is not a one-person job. It’s a mission that calls for a 𝐓𝐢𝐠𝐞𝐫 𝐓𝐞𝐚𝐦.   In our upcoming blog series, we’ll demonstrate how 2 Bridge 𝐓𝐢𝐠𝐞𝐫 𝐓𝐞𝐚𝐦 approach can transform your compound development journey. We’ll introduce you to the key players behind this strategy and share some compelling case studies that highlight our impact on both early-phase projects and later-stage submissions - illustrating how our collaborative efforts have helped bring science to life.   💡Curious to learn how we take life sciences to new heights? 👇Dive into our latest blog and stay tuned for more! #crossfuntionalteam #drugdevelopment #lifescience